Cancer cells carrying mutations in DNA repair genes, for example, the BReast CAncer gene 1 (BRAC-1), a protein that belongs to the HR pathway, are known to become particularly susceptible to treatment with PARP inhibitors [7]. This evidence concerns the gene PARP1 and cancer.